3 institutions join tests of Cel-Sci cancer drug


September 20, 1996

Cel-Sci Corp., a biotechnology company with research and development offices in Baltimore, said that three more medical institutions have agreed to participate in clinical testing of Multikine, an anti-cancer drug developed by the company.

The new institutions are Wayne State University in Detroit; Sir Mortimer B. Davis Jewish General Hospital/Lady Davis Institute for Medical Research in Montreal; and Hamilton Regional Cancer Centre, in Hamilton, Canada.

Those institutions join Hotel Dieu de Montreal Hospital in Montreal, which was the first to agree to participate in the study.

Geert Kersten, chief executive officer of the Alexandria, Va.-based company, said the company may sign up two more institutions for the study of Multikine, which is made up of proteins that help regulate the human immune system.

Kersten said the company plans to compile data from the study on the drug's safety and effectiveness on 30 patients who have advanced head and neck cancer and whose cancer has not responded to traditional treatments.

Pub Date: 9/20/96

Baltimore Sun Articles
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.